This content is only available within our institutional offering.
04 Aug 2017
Traumakine trial continues; recruitment expected to complete Q4
Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
Traumakine trial continues; recruitment expected to complete Q4
Faron Pharmaceuticals Oy (FARN:LON) | 135 -6.8 (-3.6%) | Mkt Cap: 92.9m
- Published:
04 Aug 2017 -
Author:
Dr Julie Simmonds -
Pages:
4